Two large real-world analyses presented at ACTRIMS Forum 2026 shed new light on the multiple sclerosis (MS) care continuum, ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton's tyrosine kinase (BTK ...
The Rev. Jesse Jackson, America’s most influential Black figure in the years between the civil rights crusades of the Rev. Dr. Martin Luther King Jr. and the election of Barack Obama, died on Tuesday.
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued stocks in the Biotechnology industry for Saturday, February 07, 2026. Let’s ...
The Honourable Maninder Sidhu, Minister of International Trade, concluded his visit to Singapore and Vietnam, which showcased ...
Blocked from reporting on U.S. Education Linda McMahon's visit to a Colts Neck school, the Asbury Park Press filed open records requests.
Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive multiple sclerosis (PPMS), revealing that it was at least as effective as its ...
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...
Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results